- |||||||||| Review, Journal: A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC). (Pubmed Central) - Aug 2, 2022
The preferred decades-old first line regimen was etoposide-platinum, to which ≥50% of patients respond, followed by decades-old, tired topotecan in second line for platinum sensitive patients, full stop, because there were no approved therapeutic options (nor generally any compelling experimental ones) in third line or beyond...A significant sea change occurred in 2018 with the approval of nivolumab followed by pembrolizumab and atezolizumab in 2019, durvalumab in 2020, accelerated approval for lurbinectedin in 2020 and trilaciclib in 2021 for myelosuppression...Suddenly, a tumor type, whose name was virtually synonymous with stalled progress and movement, and which was much less well studied and funded than its more prevalent cousin, non-small cell lung cancer (NSCLC), finds itself in the eye of the storm, that is, at the epicenter of an intense flurry and ferment of activity, not all of it positive. This review surveys approved drugs and select up-and-coming ones in development for extensive stage SCLC.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Real-world evidence, Real-world effectiveness, Real-world: LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) - Jun 30, 2022 P=N/A, N=200, Recruiting, Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting
|